Tegaserod

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Dyspepsia

Conditions

Dyspepsia

Trial Timeline

Sep 1, 2004 → Aug 1, 2006

NCT ID

NCT00232102

About Tegaserod

Tegaserod is a phase 3 stage product being developed by Novartis for Dyspepsia. The current trial status is completed. This product is registered under clinical trial identifier NCT00232102. Target conditions include Dyspepsia.

What happened to similar drugs?

3 of 15 similar drugs in Dyspepsia were approved

Approved (3) Terminated (3) Active (11)

🔄YM443Astellas PharmaPhase 3

🔄Cinitapride + domperidoneEisaiPhase 3

🔄Z-338Zeria PharmaceuticalPhase 3

🔄Imonogas + EspumisanJohnson & JohnsonPhase 3

✅esomeprazoleAstraZenecaApproved

✅Esomeprazole MagnesiumAstraZenecaApproved

🔄TegaserodNovartisPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00511771	Pre-clinical	Completed	—	—	Irritable Bowel Syndrome With Constipation
NCT00414024	Phase 3	Terminated	Feb 1, 2007	May 1, 2007	Opioid-induced Constipation
NCT00390975	Approved	Terminated	Jan 1, 2007	Mar 1, 2007	Gastroparesis
NCT00399659	Phase 3	Terminated	Nov 1, 2006	Apr 1, 2007	Opioid-induced Constipation
NCT00365820	Phase 2/3	Terminated	Jul 1, 2006	Apr 1, 2007	Constipation
NCT00348634	Approved	Terminated	Jul 1, 2006	Apr 1, 2007	Chronic Constipation
NCT00171457	Phase 3	Completed	Apr 1, 2005	Sep 1, 2006	Heartburn
NCT00171470	Phase 3	Completed	Apr 1, 2005	Aug 1, 2006	Dyspepsia
NCT00139568	Phase 3	Completed	Feb 1, 2005	Oct 1, 2005	Constipation
NCT00563758	Pre-clinical	Terminated	Dec 1, 2004	Feb 1, 2006	Constipation
NCT00563615	Pre-clinical	UNKNOWN	Nov 1, 2004	Oct 1, 2006	Constipation
NCT00171431	Phase 3	Terminated	Nov 1, 2004	May 1, 2006	Constipation Predominant
NCT00232037	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232102	Phase 3	Completed	Sep 1, 2004	Aug 1, 2006	Dyspepsia
NCT00232089	Phase 3	Completed	May 1, 2004	Jun 1, 2006	Dyspepsia
NCT00142974	Phase 2	Terminated	May 1, 2004	Apr 1, 2005	Diabetic Gastropathy
NCT00142987	Approved	Completed	Apr 1, 2004	Jun 1, 2005	IBS-C and IBS With Mixed Bowel Habits
NCT00149877	Approved	Completed	Apr 1, 2004	Feb 1, 2006	Chronic Constipation
NCT00141089	Phase 3	Completed	Mar 1, 2004	Feb 1, 2005	Chronic Constipation
NCT00171483	Phase 3	Completed	Jan 1, 2004	Apr 1, 2005	Gastroesophageal Reflux Disease (GERD)

Competing Products

20 competing products in Dyspepsia

See all competitors

Product	Company	Stage	Hype Score
YH12852 0.1 mg + YH12852 0.25 mg + YH12852 0.5 mg + Placebo	Yuhan	Phase 2	27
YM443 + Placebo + Moxifloxacin	Astellas Pharma	Phase 1	29
YM443	Astellas Pharma	Phase 3	40
Cinitapride + domperidone	Eisai	Phase 3	40
Rabeprazole + Rabeprazole + Rabeprazole + Placebo	Eisai	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 3	40
Imonogas + Espumisan	Johnson & Johnson	Phase 3	40
esomeprazole	AstraZeneca	Approved	43
Esomeprazole Magnesium	AstraZeneca	Approved	35
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Tegaserod	Novartis	Phase 3	40
Tegaserod and Placebo	Novartis	Approved	35
Tegaserod	Novartis	Phase 3	40
Gabapentin + Placebo	Pfizer	Phase 3	32
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338	Zeria Pharmaceutical	Phase 2	35
Z-338 + Placebo	Zeria Pharmaceutical	Phase 3	40
Acotiamide hydrochloride hydrate + Placebo	Zeria Pharmaceutical	Phase 3	44